Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe… (NCT01759121) | Clinical Trial Compass
UnknownNot Applicable
Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR
China84 participantsStarted 2016-03
Plain-language summary
This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy of 532nm laser partially subthreshold panretinal photocoagulation with PASCAL endpoint management function for severe non-proliferative diabetic retinopathy.
Who can participate
Age range45 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of severe non-proliferative diabetic retinopathy
* Age:45-80 years
* Best corrected visual acuity(BCVA) ≥20/100,Myopia≤-6 degree(-6D)
* No photocoagulation (PRP) before this clinical trial and no major ocular surgery (including cataract extraction, or any other intraocular surgery) within 3 months
* Ability and willingness to provide informed consent
Exclusion Criteria:
* Participate in other clinical trials within 3 months
* Severe refractive media turbidity; Unable to accept laser treatment such as nystagmus, etc
* Medically or mentally unstable(including cardiovascular disorders, cerebrovascular diseases,liver and kidney disease,hematological disorder and psychosis
* Conditions that in the opinion of the investigator would interfere trial results or increase risk
* Conditions that in the opinion of the investigator would preclude participation in the study